Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27178948 | 1.00 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL28535858 | 0.92 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL28638453 | 0.88 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL28528075 | 0.88 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30741698 | 0.88 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30741738 | 0.88 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30906267 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3ALDH2 | |
| SCHEMBL21906689 | 0.86 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20231475 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3ALDH2 | |
| SCHEMBL30741758 | 0.85 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |